Articles tagged "Multicenter studies"

2016 American Transplant Congress
Factors Associated with Increased Risk of MELD Progression Among a Large Population of Patients with Cirrhosis and an Initial Low MELD Score (<15).
K. Atiemo, L. Zhao, A. Skaro, L. VanWagner, S. Goel, A. Kho, B. Ho, R. Kang, S. Montag, J. Holl, M. Abecassis, D. Ladner.
Northwestern University, Chicago.
AimsLiving donor liver transplantation (LDLT) is an underutilized resource. Timely identification of patients with cirrhosis and a low MELD who's MELD score is likely to…
2015 American Transplant Congress
Remote Ischemic Preconditioning Increases Transplantation of Abdominal Organs in Standard Criteria Neurological Death Donors
A. Bongu,¹ W. Washburn,² J. Oliver,¹ J. Nespral,³ A. Davidow,⁴ C. Kadric,³ G. Dikdan,¹ J. Lewis,² U. Pandit,¹ A.-K. Beidas,¹ C. Tourtellot,³ L. Brown,¹ B. Koneru.¹
¹Surgery, Rutgers-New Jersey Medical School, Newark, NJ; ²Surgery, University of Texas Health Science Center, San Antonio, TX; ³Texas Organ Sharing Alliance, San Antonio, TX; ⁴Preventive Medicine, Rutgers-New Jersey Medical School, Newark, NJ.
Background: Remote ischemic preconditioning (RIPC) induces innate protective mechanisms in remote organs. We hypothesized RIPC soon after neurological death (ND) would improve donor organ function…
2015 American Transplant Congress
Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study
B. Orandi, X. Luo, A. Massie, J. Garonzik-Wang, B. Lonze, R. Ahmed, K. Van Arendonk, R. Montgomery, D. Segev.
Surgery, Hopkins, Baltimore, MD.
A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to…
2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
C. Sommerer,¹ K. Budde,¹ V. Kliem,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ I. Hauser,¹ P. Reinke,¹ R. Stahl,¹ T. Rath,¹ M. Porstner,² D. Baeumer,² M. Zeier,¹ W. Arns,¹ F. Lehner.¹
¹Herakles Study Group, Germany; ²Novartis Pharma, Nuremberg, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…
2015 American Transplant Congress
Multicenter Study to Develop a Novel Prediction Index for Hepatocellular Carcinoma (HCC) Recurrence After Liver Transplant (LT)
N. Mehta,¹ J. Heimbach,² D. Harnois,³ J. Dodge,¹ J. Burns,³ D. Lee,³ W. Sanchez,² J. Roberts,¹ F. Yao.¹
¹UCSF, San Francisco, CA; ²Mayo Clinic, Rochester, MN; ³Mayo Clinic, Jacksonville, FL.
Several factors have been associated with a high risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), but no reliable risk score has…
2015 American Transplant Congress
Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses
U. Eisenberger,¹ K. Budde,¹ O. Witzke,¹ F. Lehner,¹ C. Sommerer,¹ R. Wuethrich,³ P. Reinke,¹ A. Muehlfeld,¹ K. Heller,¹ R. Stahl,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,² W. Arns.¹
¹ZEUS Study Group, Germany; ²Novartis, Pharma, Germany; ³ZEUS Study Group, Switzerland.
Background: Analysis of pathologists' assessments and histological data allow for deeper insight on patient outcome together with investigator's final clinical diagnoses. Here we present 5…
2015 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48
K. Budde,¹ C. Sommerer,¹ P. Weithofer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ I. Hauser,¹ R. Stahl,¹ P. Reinke,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ W. Arns.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To follow up on renal function (GFR) at month (Mo) 48 after kidney transplantation (Tx) in patients (pts) on immunosuppressive regimen with different calcineurin…
2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
W. Arns,¹ K. Budde,¹ C. Sommerer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ P. Reinke,¹ I. Hauser,¹ R. Stahl,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ V. Kliem.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…
2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
F. Lehner,¹ K. Budde,¹ R. Wuethrich,² P. Reinke,¹ W. Arns,¹ A. Muehlfeld,¹ U. Eisenberger,¹ R. Stahl,¹ K. Heller,¹ O. Witzke,¹ B. Suwelack,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,³ C. Sommerer.¹
¹ZEUS Study Group, Germany; ²ZEUS Study Group, Switzerland; ³Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…
2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
K. Trobaugh,¹ A. Shields,^1,2 S. Tremblay,¹ R. Alloway,¹ M. Cardi,² D. Witte,¹ F. Paterno,¹ M. Cuffy,¹ E. Woodle.¹
¹Univ of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…